Chemed Corporation CHE

Chemed has gained 20.9% year to date, prompting questions about whether the price reflects the cash Chemed can generate. The company’s two main operations— hospice care and its Roto-Rooter plumbing business—face a new dynamic after Roto-Rooter bought its largest independent franchise territory, potentially shifting cash retention versus payments to franchisees. A discounted cash flow model suggests Chemed’s intrinsic value is meaningfully above the current share price of about $512, implying the market is pricing a more cautious cash-flow outlook. LTM free cash flow runs around $331 million, and the 2-stage model projects growth through 2027. The narrative of Chemed being undervalued by roughly 7% centers on its strong operating cash flow, low leverage, and capital returns, though the new franchise arrangement adds uncertainty about margins and investment needs. In-house expansion of Roto-Rooter territory could materially shift cash retention and valuation, altering Chemed's future trajectory.

Chemed Corporation (CHE) announced that its Roto-Rooter Services Company subsidiary has acquired the largest independent Roto-Rooter franchise for $60.6 million. The California territories cover about 11 million people and produced annual revenue in the $50–$55 million range before the deal. At the purchase price, valuation is roughly 1.10–1.21 times historical revenue. The investment’s value hinges on how much profit and cash ownership can generate after operating costs and reinvestment. Bulls say the deal leverages an existing brand with California-market exposure (Sacramento, Fresno, Northern San Diego) and allows direct control over scheduling, purchasing, training, and service standards, potentially boosting margins through efficiency even without higher sales. Bears note missing disclosed earnings or synergies, potential integration costs, and the need to convert operating earnings to cash amid fleet, labor, and working-capital needs. Hedge-fund sentiment appears mixed following the news. Acquisition could improve margins and cash flow if integration costs are manageable, but lack of disclosed earnings and synergies leaves upside uncertain.

Roto-Rooter, a Chemed Corporation subsidiary, purchased its largest franchisee territory. Acquisition consolidates control over major operations and may improve efficiency.

Chemed deepens share buybacks amid mounting activist pressure, highlighting questions over its capital allocation and strategic response. Activist-driven buybacks signal capital allocation shifts that can sway investor sentiment and short-term valuation without transforming core operations.

Chemed Q2 results show VITAS segment growth offset by Roto-Rooter marketing pressures that shape the company outlook. Q2 segment results point to moderate effects on financial trajectory without fundamental shifts.

Chemed Corp reported Q2 2026 earnings with strong Vitas segment performance and ongoing strategic initiatives. Positive Vitas results and strategic updates can moderately affect near-term financials and investor views.

Chemed Q2 earnings call highlighted financial results, operational performance and strategic updates for the company. Quarterly earnings updates provide moderate insight into near-term performance without indicating major strategic shifts.

Chemed Corporation conducted its Q2 2026 earnings call covering financial results and outlook. Earnings call details can influence near-term investor sentiment and stock valuation.

Chemed (NYSE:CHE) exceeded Q2 CY2026 expectations. Earnings beat provides moderate positive signal for near-term performance and sentiment.

Chemed Corporation reported its second-quarter 2026 financial results. Quarterly results provide updated financial metrics that can shift near-term investor views on performance.

Chemed Corporation prepares to release Q2 earnings with focus on revenue, EPS, and segment results from VITAS hospice care and Roto-Rooter services. Quarterly earnings expectations can shift near-term investor sentiment and valuation but rarely alter long-term company trajectory.

Chemed Corporation's stock has been depressed by market overreaction to two temporary disruptions, treating them as permanent setbacks and creating undervaluation. Mispricing temporary disruptions as permanent creates significant upside potential for Chemed's future performance and investor sentiment upon correction.

Chemed Corporation (CHE) released highlights from its Q1 earnings call. Q1 earnings call highlights detail financial results and forward guidance that significantly influence stock performance and investor outlook.

Chemed Corporation (CHE) stock rose after Q1 earnings and revenue surpassed expectations, despite declining margins. Q1 earnings and revenue beat boosted stock price short-term, but margin decline tempers broader trajectory impact.

Chemed Corporation beat earnings expectations with strong margins in its VITAS hospice segment, prompting a valuation analysis that underscores improved financial health and growth prospects. Earnings beat and VITAS margin strength signal robust financial performance, enhancing investor sentiment and valuation multiples.

Chemed Corporation's Q1 results highlight VITAS segment driving revenue growth, while Roto-Rooter adapts to elevated marketing costs amid steady performance. VITAS growth boosts overall earnings, countering Roto-Rooter's cost pressures and signaling positive trajectory for Chemed's dual-segment operations.

Chemed Corp's Q1 2026 earnings call highlighted strong VITAS segment performance offsetting Roto-Rooter challenges. Strong VITAS results signal significant positive impact on Chemed's financial trajectory despite Roto-Rooter headwinds.

Chemed Corporation reported Q1 2026 earnings with key financial metrics, operational updates from Vitas Healthcare and Roto-Rooter segments, revenue growth, EPS figures, and forward guidance amid market conditions. Quarterly earnings summaries influence financial performance and investor sentiment but are balanced by annual trends.

Chemed Corporation (CHE) beat first-quarter earnings and revenue estimates. Beating Q1 earnings and revenue estimates signals strong financial performance, likely driving positive investor sentiment and stock price gains.

Chemed Corporation (NYSE:CHE) reported Q1 CY2026 sales surpassing estimates, propelling its stock up 10.2%. Exceeding sales estimates triggered a 10.2% stock surge, indicating strong financial momentum with significant positive effects on investor sentiment and performance trajectory.

Chemed Corporation reported first-quarter 2026 results, highlighting key financial metrics and operational performance. Quarterly earnings reports provide insights into financial health and operations, moderately influencing market performance and investor sentiment.

Analysts outline expectations for Chemed Corporation (CHE) Q1 earnings, projecting revenue growth, EPS figures, and guidance amid hospice and plumbing segment performance. Pre-earnings previews moderately influence investor sentiment and stock volatility ahead of actual results.

Analysts forecast Chemed Corporation (CHE) to report declining earnings, highlighting key factors to monitor ahead of the release. Expected earnings decline could noticeably affect Chemed's short-term financial results and market sentiment.

Chemed Corporation announced a five-year amended and restated credit agreement totaling $450 million. The $450 million five-year credit agreement provides substantial financial flexibility for operations, acquisitions, and growth initiatives.

Chemed's Roto-Rooter buys out urban franchises, potentially boosting margins through direct control and enhancing scale in key markets, shifting the bull case positively. Roto-Rooter’s urban franchise buyout represents a major strategic shift enabling direct operations for improved margins and expanded scale.

Roto-Rooter, a Chemed Corporation (CHE) subsidiary, completed acquisitions of two significant territories to expand its plumbing services operations. Acquisitions of significant territories represent a major strategic expansion for Roto-Rooter, strengthening Chemed's market position and growth trajectory.

Chemed Corporation delivered a weak quarter with an earnings per share miss, prompting investors to reassess risks amid concerns over future performance. EPS miss and weak quarterly results signal major pressures on financial performance and investor confidence.

Chemed Corporation (CHE) stock declined 6.2% since its last earnings report, underperforming the industry's 1.5% drop and S&P 500's gain, driven by a negative earnings surprise, weak Vitas Healthcare performance, and downward earnings estimate revisions. Post-earnings 6.2% stock drop highlights moderate concerns over financial results and segment weakness, influencing short-to-medium term performance.

Chemed Corporation (CHE) warrants selling due to three key reasons, with one alternative stock recommended as a buy instead. Bearish recommendations target CHE's vulnerabilities, likely influencing investor sentiment and short-to-medium-term performance.

Chemed Corporation (CHE) missed earnings expectations and issued softer 2026 guidance, prompting analysts to reassess its valuation. Earnings miss and softer 2026 guidance signal potential financial weakness, significantly impacting Chemed's stock performance and investor sentiment.